XNK Therapeutics names new CEO

Johan Liwing, from Janssen (Johnson & Johnson), has been appointed new acting CEO at XNK Therapeutics. He is succeeding the former CEO Karin Mellström whom will retire, but remain disposable for the the company as Project Manager. Johan Liwing has over 15 year’s of experience from leading positions within the Life science industry in Sweden as well as internationally. During his 13 years at Janssen (Johnson & Johnson), he has held various positions in health economics, sales & marketing, as well as observational research. In his most recent position at Janssen, as global senior director, he was responsible for the development and use of observational data.